Author

M. Marcoulis

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Organism:human· 2 Assay:proteomics· 2 Approach:statistical model· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Assay:ChIP-seq· 1 Approach:deep learning· 1

Frequent Co-Authors

Y.-H. T. Lin· 2 shared A. Kang· 1 shared A. Kishishita· 1 shared A. P. Wiita· 1 shared A. Wiita· 1 shared B. G. Barwick· 1 shared B. Hann· 1 shared B. Patino Escobar· 1 shared

Activity by Year

2019-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Y.-H. T. Lin

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Functional multi-omics reveals genetic and pharmacologic regulation of surface CD38 in multiple myeloma

P. Choudhry, C. Kasap, B. Patino Escobar, O. Gugliemini, H. Geng, V. Sarin, A. Kang, A. Kishishita, S. Rampersaud, L. Sarah, Y.-H. T. Lin, N. Paranjape, P. Ramkumar, M. Marcoulis, D. Wang, , A. Wiita

This study uses multi-omics approaches to identify regulators of CD38 surface expression in multiple myeloma and assess the impact of therapies on CD38 levels and signaling.

bioRxiv · Aug 4, 2021 · PreprintCancer Biology

Integrated Phosphoproteomics and Transcriptional Classifiers Reveal Hidden RAS Signaling Dynamics in Multiple Myeloma

Y.-H. T. Lin, G. P. Way, B. G. Barwick, M. C. Mariano, M. Marcoulis, I. D. Ferguson, C. Driessen, L. H. Boise, C. S. Greene, A. P. Wiita

The paper uses phosphoproteomics and transcriptomics to analyze RAS signaling in multiple myeloma, identifying distinct signaling patterns and clinical outcomes associated with NRAS and KRAS mutations.

bioRxiv · Feb 28, 2019Cancer Biology